Drug Profile

KB 111

Alternative Names: KB-111

Latest Information Update: 13 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Krystal Biotech
Class Gene therapies; Skin disorder therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Benign Familial Pemphigus

Most Recent Events

13 Nov 2025 Pharmacodynamics data from a preclinical study in Hailey-hailey disease released by Krystal Biotech prior to November 2025
03 Nov 2025 Preclinical trials in Benign familial pemphigus in USA (Topical)
03 Nov 2025 Krystal Biotech plans a phase I trial for Benign familial pemphigus in first half of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com